Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-08-12
1999-09-21
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
549475, A61K 3134, C07D30712
Patent
active
059554967
ABSTRACT:
The present invention provides novel biologically active tetrahydrofuran diols of arachidonic acid.
REFERENCES:
patent: 4088779 (1978-05-01), Vlattas
patent: 5445956 (1995-08-01), Hammock et al.
patent: 5455271 (1995-10-01), Yuan et al.
patent: 5488033 (1996-01-01), Wei
patent: 5504111 (1996-04-01), Flavin et al.
patent: 5530114 (1996-06-01), Bennett et al.
patent: 5593990 (1997-01-01), D'Amato
Bone, "Toward an Epidemiology and Natural History of SIRS (Systemic Inflammatory Response Syndrome)," JAMA, 268:24, pp. 3452-3455 (Dec. 23/30, 1992).
Borhan et al., "Stereochemical Aspects of Cytosolic Epoxide Hydrolase Hydration of Methyl Diepoxystearates," Tetrahedron, 49:13, pp. 2601-2612(1993).
Borhan et al., "Improved Radiolabeled Substrates for Soluble Epoxide Hydrolase," Analytical Biochemistry, 231, pp. 188-200 (1995).
Cheek et al., "Ozone Injury to Alveolar Epithelium in Vitro Does Not Reflect Loss of Antioxidant Defenses," Toxicology and Applied Pharmacology, 125, pp. 59-69 (1994).
Demling, "The Modern Version of Adult Respiratory Distress Syndrome," Annu. Rev. Med., 46, pp. 193-202 (1995).
Dietze et al., "Inhibition of Cytosolic Epoxide Hydrolase by trans-3-Phenylglycidols," Biochemcial Pharmacology, 42:6, pp. 1163-1175 (1991).
Dietze et al., "Spectrophotometric Substrates for Cytosolic Epoxide Hydrolase," Analytical Biochemistry, 216, pp. 176-187 (1994).
Dobbs et al., "An Improved Method for Isolating Type II Cells in High Yield and Purity,"Am. Rev. Resp. Dis., 134, pp. 141-145 (1986).
Grant et al., "Development of and In Situ Toxicity Assay System Using Recombiant Baculoviruses," Biochemical Pharmacology, 51, pp. 502-515 (1996).
Grnykiewicz et al., "A New Generation of Ca.sup.2+ Indicators with Greatly Improved Fluorescence Properties," J. Biological Chemistry, 260:6, pp. 3440-3450 (Mar. 25, 1985).
Ingram, R.H. Jr., Harrison's Principals of Internal Medicine, 13, p. 1240 (1995).
Miyamoto et al., "Inhibition of Epoxide Hydrolases and Glutathione S-Transferases by 2-,3-, and 4-Substituted Derivatives of 4'-Phenylchalcone and its Oxide," Arch. Biochem. & Biophys., 254, pp. 203-213 (Apr. 1987).
Mullin and Hammock, "Chalcone Oxides --Potent Selective Inhibitors of Cytosolic Epoxide Hydrolase," Archives of Biochemistry and Biophysics, 216:2, pp. 423-439 (Jul. 1982).
Witrom and Hammock, "Continuous Spectrophotometric Assays for Cytosolic Epoxide Hydrolase," Analytical Biochemistry, 174, pp. 291-299 (1988).
Moghaddam et al., "Bioactivation of Leukotoxins to Their Toxic Diols by Epoxide Hydrolase," Nature Medicine, 3(5), May 1997, pp. 562-566.
Moghaddam et al., "Novel Metabolic Pathways for Linoleic and Arachidonic Acid Metabolism," Biochimica et Biophysica Acta, 1290, 1996, pp. 327-339.
Borhan Babak
Cheek Jeffrey M.
Fergusson James
Grant David F.
Greene Jessica F.
Spivack Phyllis G.
The Regents of the University of California
LandOfFree
Dihydroxy-oxy-eicosadienoates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dihydroxy-oxy-eicosadienoates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydroxy-oxy-eicosadienoates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-80734